Investors may doubt the company's ability to improve sluggis...
Investors may doubt the company's ability to improve sluggish revenue, despite a superior outlook. Market hesitation could be due to priced-in risks, though a share price plunge seems unlikely given high growth forecasts.
Not Many Are Piling Into Apyx Medical Corporation (NASDAQ:APYX) Stock Yet As It Plummets 26%
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more
Comment
Sign in to post a comment